How a medspa orders compounded GLP-1s within the rules

In short. Compounding a copy of an approved GLP-1 is no longer covered by a shortage. A 503A pharmacy compounds on a valid prescription for an identified patient, and a compounded product that is essentially a copy of the approved drug needs a prescriber’s documented reason that the change makes a significant difference for that patient. Office stock is a different kind of order, and the prescription is always the prescriber’s.

What changed when the shortages ended

While a drug is on FDA’s shortage list, pharmacies may compound copies of it. Once the shortage is resolved, that allowance ends after a period of enforcement discretion. For the two GLP-1 drugs most medspas prescribed, FDA’s own timeline is:

Many articles still give February 18 and April 22, 2025 for the 503A dates. Those were the dates FDA first announced; its page now ties the end to the court rulings. Either way, the shortage allowance is over.

What a compliant 503A order needs now

A 503A pharmacy is a state-licensed pharmacy compounding for individual patients. Federal law expects each compounded drug to be dispensed on a valid prescription for an identified patient. For a compounded GLP-1, three things carry most of the weight:

• A real patient-specific prescription. A named patient, a prescriber licensed in the state where the patient is, and every element your state requires on a prescription.
• A documented clinical reason, when the product is close to the approved drug. FDA says it does not treat a compounded product as essentially a copy when a prescriber determines and documents that it contains a change that produces a significant difference for an identified individual patient. That decision and its documentation belong to the prescriber, in your clinical record.
• A lawful active ingredient. FDA says semaglutide sodium and semaglutide acetate are different active ingredients from those in the approved drugs and that it knows of no lawful basis for compounding with them. Ask what the pharmacy uses and where it comes from.

FDA also states that compounded drugs should be used only for patients whose medical needs cannot be met by an approved drug, and it has received reports of dosing errors with compounded semaglutide, some from miscalculated doses. Clear units and directions on every prescription matter.

Office stock is a different order

A patient prescription is not a way to buy practice stock. Under section 503A, compounding is tied to identified patients; office-use supply without a patient-specific prescription is what registered 503B outsourcing facilities are for, under FDA registration and manufacturing standards. FDA’s discretion for 503B copies of tirzepatide and semaglutide ended on the dates above, so ask any outsourcing facility how a product it offers meets the law today. The 503A vs 503B article sets the two side by side.

A checklist for every order

1. The prescriber holds an active licence in the patient’s state.
2. The prescription names the patient and carries every required element, with the quantity in unambiguous units.
3. Any clinical reason for a compounded product is documented by the prescriber in your record.
4. The pharmacy is licensed where it is and in the patient’s state, and you know which pharmacy filled the order.
5. The order, its signature, its payment and its shipment are kept together, where they cannot be edited later.

Review your advertising too: the American Med Spa Association advises practices to update promotional materials that relied on the shortage.

Where TrueRoute fits

TrueRoute is prescription ordering and pharmacy operations software, not a pharmacy, and it never prescribes. The prescription screen carries every element a valid prescription requires and freezes them when the prescriber signs; the prescriber sets the product, quantity and directions. Before anything is charged, TrueRoute checks what it can check, including the prescriber’s licence in the patient’s ship-to state as attested, and selects the fulfillment route under a written routing policy. Prescribers are NPI-validated and clinic-attested. Office-use purchasing is a separate purchase order, available once your account’s program is set up, and every order keeps its status, payment and fulfillment on one append-only record.

How the two ordering paths work · Security and compliance

Questions

Sources

1. FDA, “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize” (content current as of April 1, 2026)
2. FDA, “FDA’s concerns with unapproved GLP-1 drugs used for weight loss” (content current as of October 1, 2026)
3. FDA, “Human drug compounding laws” (sections 503A and 503B of the FD&C Act)
4. FDA, “Prescription requirement under section 503A of the Federal Food, Drug, and Cosmetic Act”, final guidance for industry (December 2016)
5. FDA, “Compounded drug products that are essentially copies of a commercially available drug product under section 503A”, final guidance (January 2018)
6. American Med Spa Association, “Compounded GLP-1 FAQ” (March 2025)

Rules change. Confirm what applies to your clinic with your state board of pharmacy, your medical board and your own counsel.